Applied Pharma Research s.a.
APR Applied Pharma Research s.a. (APR) is a Swiss Pharma company dedicated to providing patients suffering from rare diseases with innovative treatments that make a real difference in their life. Our focus as a Swiss global health care company is the identification, research, development, manufacturing, registration and commercialization of innovative, proprietary, science driven products designed to address patient´s needs in niche and rare therapeutic areas on a global basis. APR APPLIED PHARMA RESEARCH has a proven track record in developing branded and patented products worldwide. APR provides a wide range of services for the pharmaceutical industry on a contract basis and on a fee for service basis: research and development services with complete supervision, management and execution of the entire project, development of oral and topical formulations and customized drug delivery technologies.
Counts on a balanced mix of marketed, revenue-generating products and a compelling pipeline of innovative products in rare indications at different stages of development, with main focus on rare recessive metabolic diseases, rare dermatological diseases and ocular diseases.
Offers late-stage licensing opportunities for internally developed products.
Provides a complete and vertically integrated range of contract R&D services - from formulation to regulatory support on an international basis.
PHARMACEUTICAL RESEARCH AND DEVELOPMENT OUR NETWORK WORLDWIDE
The company is headquartered in Switzerland. With our extensive network of commercial partners, APR's products are distributed in more than 70 countries worldwide, whereas the Company distributes and markets directly with its own sales and marketing organization a selection of our products in rare diseases field in selected countries of Europe.
Providing Value for Patients Suffering from Rare Diseases
As a Swiss based healthcare company with a global reach, we identify, develop and commercialize science driven branded products on a global basis, which can provide significant benefits over existing options in the treatment of niche and rare diseases through improved efficacy, safety or patient convenience.
We build value thanks to our outstanding ability to combine drug development expertise with proprietary drug delivery technologies to deliver to patients suffering from rare diseases with solution meaningfully improving their life and empowering caregivers with better tools to manage such rare diseases.
We are committed to delivering innovation in treating rare and orphan diseases as the result of a validated process divided in three steps:
The cornerstones of our strategy are the following:
Innovation: Starting from a deep understanding of the patient journey, we identify still unmet medical needs in specialized therapeutic areas or the rare/orphan diseases field to be addressed through drug repurposing or the application of novel drug delivery technologies (preferably platform technologies protected by international patents), which are potentially applicable to several drug candidates in different therapeutic areas.
Development: Products are internally developed and financed (independently or with our co-development partners who are able to provide complementary know-how and competencies) by directly managing and controlling the key steps of the process - from proprietary technologies applications and/or novel dosage forms finalization to pre-clinical and clinical activities, market authorization and regulatory approval obtainment. In case of need, we enter into strategic outsourcing relationships to complete the development as well as to manufacture our product candidates in a cost-effective manner.
Partnering: We rely on solid companies for distribution, promotion, marketing and commercialization of our products on a worldwide basis.
Marketing: We promote and market selected products of our range in rare/orphan diseases with our own sales force and infrastructure in selected strategically significant countries.
Service: We support third party projects by offering pharma companies high-value contract development services based on advanced patented technologies, know-how and world-class pharma development expertise.
We employ a project management approach that allows us to synchronize and manage all phases of product development in order to minimize time, risks and reduce costs.
APR focuses on scientifically driven risk/benefit analysis combined with patient/consumer need evaluation process and integrating product characteristics with regulatory and investment information.
As healthcare company, we focus on a scientifically driven risk/benefit analysis combined with a patient/consumer need evaluation process and on integrating product characteristics with regulatory and investment information.
We work closely with authorities in Europe and the USA to provide the optimal strategy for regulatory approval, in order to be able to quickly distribute the products in as many geographies as possible.
We are able to develop the optimal formulation and its related delivery format which best addresses the identified need; We also employ specialists with an in-depth knowledge of a given healthcare product's physical and chemical characteristics - fundamental in determining optimal formulations and dosing characteristics to meet our clients' and patients'/consumers' needs.
We take an integrated multi-phase approach on pre-formulation development, compatibility tests, prototype development, stability studies, scaling-up and validation to clinical trials and registration.
Your Swiss Pharma Company
APR Applied Pharma Research s.a. (APR) is a Swiss, private Pharma company, located in Balerna (Ticino area), the science valley in the southern part of Switzerland.
The company is focused on development and commercialization of innovative, science-driven products designed to address unmet needs in niche or rare therapeutic areas on a global basis.
APR combines drug development expertise with proprietary drug delivery technologies to deliver to patients suffering from rare diseases with solutions meaningfully improving their life and empowering caregivers with better ways to manage such rare diseases.
APR has a balanced portfolio of revenue-generating branded products marketed in all major markets, combined with a compelling pipeline of innovative products at different stages of development, specifically in the treatment of rare recessive metabolic disorders, rare dermatological and ocular diseases.
Our main marketed products are:
- PKU GOLIKE®, an innovative food for special medical purposes (FSMP) consisting of a Phe-free amino acid mixture, powered by the patented Physiomimic™ Technology, for Phenylketonuria (PKU) dietary management
- Nexodyn® AcidOxidizing Solution (AOS), the advanced wound cleanser for acute and chronic wound management, powered by the patented Tehclo™ Technology Platform
- An immediate release formulation of Diclofenac K for the treatment of migraine and acute pain powered by the patented Dynamic Buffering Technology;
- Setofilm®, an oral film formulation of Ondansetron indicated for cancer supportive care (in the treatment of CINV, RINV and PONV), powered by the patented Oral Dispersible Film (ODF) technology;
Using various delivery technologies, APR has also developed some Category OTC Healthcare Brands such as Halykoo® and SwitzAGE™.
HalyKoo® consists of a complete range of high-quality health care solutions specifically tailored to baby needs, while SwitzAGE™ is an innovative range of nutraceuticals, 100% Swiss made, specifically created to meet adults' wellbeing needs.